Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLuciano da Fontoura CostaSMSalomon ManierPVPeter M. Voorhees

Discussion

Loading...

Member takes

Overview

Randomised trial shows improved progression-free survival in standard-risk multiple myeloma patients receiving cilta-cel, suggesting its potential as a key treatment option.

Key Points

  • To evaluate the efficacy of ciltacabtagene autoleucel in patients with standard-risk cytogenetics in multiple myeloma.
  • Conducted CARTITUDE-4 study with patients who are lenalidomide-refractory multiple myeloma.
  • Patients received cilta-cel after apheresis and bridging therapy with pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone.
  • Measured progression-free survival using next-generation sequencing and MRD-negative criteria.
  • 30-month progression-free survival rate was 80.5% in the as-treated population with standard-risk cytogenetics.
  • Patients achieving MRD-negative complete response at 12 months had a 100% progression-free survival at 30 months.
  • Comparison showed improved survival rates in standard-risk patients receiving cilta-cel versus previous CARTITUDE-1 results.

Cite This Study

Costa et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d056https://doi.org/10.1182/blood-2025-94
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.2023 · 117 citations
  2. 2Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma2025 · 111 citations
  3. 3Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma2025 · 3 citations
  4. 4Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma2025
  5. 5Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study2025 · 3 citations